Cargando…
Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis
Atherosclerosis affects millions of people worldwide. However, the wide variety of limitations in the current therapeutic options leaves much to be desired in future lipid-lowering therapies. For example, although statins, which are the first-line treatment for coronary heart disease (CHD), reduce t...
Autores principales: | Valanti, Eftaxia-Konstantina, Dalakoura-Karagkouni, Katerina, Sanoudou, Despina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313318/ https://www.ncbi.nlm.nih.gov/pubmed/30282955 http://dx.doi.org/10.3390/jpm8040034 |
Ejemplares similares
-
HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis
por: Chyu, Kuang-Yuh, et al.
Publicado: (2015) -
HDL-apoA-I Exchange: Rapid Detection and Association with Atherosclerosis
por: Borja, Mark S., et al.
Publicado: (2013) -
Different Functional and Structural Characteristics between ApoA-I and ApoA-4 in Lipid-Free and Reconstituted HDL State: ApoA-4 Showed Less Anti-Atherogenic Activity
por: Yoo, Jeong-Ah, et al.
Publicado: (2015) -
Effect of apoA-I Mutations in the Capacity of Reconstituted HDL to Promote ABCG1-Mediated Cholesterol Efflux
por: Daniil, Georgios, et al.
Publicado: (2013) -
Correction: Effect of apoA-I Mutations in the Capacity of Reconstituted HDL to Promote ABCG1-Mediated Cholesterol Efflux
Publicado: (2014)